<DOC>
	<DOCNO>NCT00660647</DOCNO>
	<brief_summary>Optimized treatment algorithm early rheumatoid arthritis : Methotrexate intra-articular glucocorticosteroid plus adalimumab placebo treatment early rheumatoid arthritis . A Randomised , double-blind placebo-controlled , two arm , parallel group study additive effect adalimumab concern inflammatory control inhibition erosive development . Optimized Treatment Algorithms Patients Early RA</brief_summary>
	<brief_title>Optimized Treatment Algorithm Patients With Early Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description>In newly diagnose rheumatoid arthritis patient recommend treat soon possible methotrexate steroid However , treatment algorithm , bring one third patient remission stop progressive , persistent joint damage . The possible benefit risk add adalimumab conventional treatment algorithm unknown . The aim study clarify possible benefit add adalimumab anti-TNF-alfa inhibitor versus placebo treatment rheumatoid arthritis patient , treat early give methotrexate intraarticular triamcinolone hexacetonide . Efficacy evaluate DAS 28 , ACR 20/50/70 , HAQ , progressive change X-ray , MRI DXA-scans . Adverse event also register .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<criteria>1 . Patients ( 18 year ) rheumatoid arthritis accord ACR classification criterion ( 1 ) diagnose &lt; 6 month . 2 . Moderate severe rheumatoid arthritis define DAS28 ( CRPbased ) &gt; 3.2 . 3 . Negative pregnancy test ( serum HCG ) woman childbearing potential prior trial start . ( Nonfertile woman define postmenopausal least 1 year surgical sterilisation ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) ) . Fertile woman include trial use contraception entire trial period ( i.e . one follow method : Oral contraception , intrauterine device ( IUD ) , depot injection progesterone , subdermal implantation , contraceptive vaginal ring , transdermal depot plaster ) . In addition , contraception use period 150 day discontinuation trial medicine . 4 . Ability willingness inject sc . injection him/herself assistant give injection . 5 . Ability willingness give write informed consent meet requirement trial protocol . 1 . Persons latent TB define positive Mantoux test ( &gt; 12 mm vaccinate 6 mm nonvaccinated ) , positive cultivation mycobacteria tissue sample , chest Xray indicate TB , risk factor activation untreated latent TB , person give adequate TB prophylaxis accord instruction department . 2 . Active recurrent infection severe infection require hospitalization treatment i.v . antibiotic within last 30 day oral antibiotic within last 14 day prior inclusion 3 . Positive serology Hepatitis B C indicate active infection . 4 . Medical history positive HIV status ( Check HIV test upon suspicion ) . 5 . Medical history histoplasmosis listeriosis . 6 . Previous cancer lymph proliferative disease except case teated radically without relapse minimum 5 year . Patients previous squamous cell carcinoma , basal cell skin carcinoma cervical dysplasia , treat successfully radically include . 7 . Previous diagnosis sign demyelinized disease CNS system ( e.g . optic neuritis , visual disorder , disturbed gait , facial paralysis , apraxia ) . 8 . Severe renal insufficiency ( creatinine clearance &lt; 35 ml/min nomogram ) . 9 . Affected liver function : Liver enzymes &gt; 2 x normal limit value . 10 . Clinical significant drug alcohol abuse past year and/or current daily alcohol consumption . 11 . Unstable diabetes , unstable ischemic heart disease , heart insufficiency ( NYHA IIIIV ) , active chronic inflammatory intestinal disease , recent cerebral apoplexia ( within 3 month ) , chronic leg ulcer condition ( e.g . kateter demeure ) accord investigator imposes increase risk subject , he/she participates protocol . 12 . Anticoagulant therapy . 13 . Pregnancy breastfeed . 14 . Other inflammatory rheumatic disease . 15 . Aggressive parvovirus B19 infection . 16 . Previous treatment one DMARDs . 17 . Glucocorticosteroid treatment within last 4 week ( except nasal inhalation steroid ) . 18 . Contraindications trial medicine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Rheumatoid arthritis , adalimumab , efficacy , adverse event</keyword>
</DOC>